Molecular imaging ͑MI͒ constitutes a recently developed approach of imaging, where modalities and agents have been reinvented and used in novel combinations in order to expose and measure biologic processes occurring at molecular and cellular levels. It is an approach that bridges the gap between modalities acquiring data from high ͑e.g., computed tomography, magnetic resonance imaging, and positron-emitting isotopes͒ and low ͑e.g., PCR, microarrays͒ levels of a biological organization. While data integration methodologies will lead to improved diagnostic and prognostic performance, interdisciplinary collaboration, triggered by MI, will result in a better perception of the underlying biological mechanisms. Toward the development of a unifying theory describing these mechanisms, medical physicists can formulate new hypotheses, provide the physical constraints bounding them, and consequently design appropriate experiments. Their new scientific and working environment calls for interventions in their syllabi to educate scientists with enhanced capabilities for holistic views and synthesis.
I. INTRODUCTION
Over the last 30 years we have experienced a rapid evolution of technology which has led to a transformation of biological and medical sciences. Biological entities and mechanisms that the limitations of technology until recently did not allow us to observe have now become an object of routine measurement and reasoning. A typical field of application of this change is medical imaging. Until the early 1970s, the study of the human body was based on imaging modalities that produced projections, exploiting a variety of physical properties of the human tissues. Three dimensional ͑3D͒ representations were rarely achieved through time-consuming and mainly experimental procedures, producing rather vague final results. In contrast, modern routine medical diagnostic imaging heavily relies on modalities that produce highresolution 3D representations of the human body featuring both morphological and functional characteristics. The latter often require four dimensional images, by combining the three dimensional spatial information with other types of information, e.g., temporal, spectroscopic, etc.
Although computed tomography ͑CT͒ and magnetic resonance imaging ͑MRI͒ were initially considered to be inefficient, as it is vividly described in a recent article by Wagner, 1 they proved to be indispensable medical diagnostic modalities. These modalities are mathematically ill-conditioned problems. As such, much experimentation and cultivation of ideas was necessary to make them appropriate for providing clinically useful images. Instrumentation for functional tomographic imaging evolved along a path distinct from that of anatomical imaging devices ͑CT and MRI͒. The first human tomographic images with positron-emitting isotopes ͑PET͒ were presented in 1972, 2 followed by single photon emission tomography ͑SPECT͒ in 1973. 3, 4 Until the early 1990s, the evolution of ideas and experiments within each modality occurred in a relative solitude to other modalities. It was an era in which continuous improvement of instrumentation specifications was the driving force behind the progress in diagnostic capabilities and effectiveness.
While the usefulness of combining anatomical and functional planar images was evident to physicians even in the 1960s, 5 preceding the invention of CT, the first prototypes combining two imaging modalities ͑SPECT/CT, PET/CT͒ capable of acquiring images within the same reference frame appeared only in the late 1990s. 6, 7 Ironically, 8 while the preclinical designs and early clinical prototypes were received with enthusiasm, the introduction of commercial PET/CT scanners into the clinic encountered a certain amount of resistance. The technology was accused of being disruptive, 9 expensive, 10 wasteful of resources, clinically unproven, 11 oversold ͑for treatment planning͒, 12, 13 and successful only as a consequence of the marketing strategy of major equipment vendors. 11 It was, however, a manifestation of a new paradigm in the field of medical imaging.
As computer power increased exponentially and became more readily available, medical physicists joined scientists from other disciplines in their new perspective for tackling with the primary clinical tasks; that of exploring and measuring the benefit of combining the available information that originated from apparently disjoint modalities and was encapsulated into data of variable levels of complexity. The field of medical informatics attracted the spotlight since the combination of information attained its own distinctive role as a major factor for achieving better health care. 14, 15 In our time, the scientific vernacular of biology and medicine has been augmented with a multitude of new terms, describing the function of genes, proteins, and cells. The advances in mass spectrometry, cell sorting, and development of microarrays, with substantial contribution of physicists, are feeding the biomedical field with an abundance of data, driving it toward a molecular perspective. A formidable number of variables are being recorded, pertaining to the diverse biological mechanisms inherent to the function of a living organism. Based on different levels of biological organization, the data can be classified into: genetic, genomic and proteomic, cellular, tissue, organ, and organism ͑Table I͒. Within this continuum, data originating from higher levels of biological organization can be defined as high-level data, whereas those originating from lower levels of biological organization can be defined as low-level data. Each level is studied with specific acquisition modalities and methods of analysis, giving rise to a large variety of "omics." 16 Unfortunately, these data cannot be directly utilized. The ocean of electronic data at our disposal is stored in a mosaic of heterogeneous database implementations, hindering the access to and aggregation of data across implementations and creating a large gap between their potential and effective value. 17 The application of various measurement protocols customized for the specific experimental conditions introduces another source of data inhomogeneity.
The advent of molecular imaging ͑MI͒ is further changing our approach to research and patient care by directly targeting the molecular, cellular, or physiologic defects responsible for disease. It offers a promise for more precise disease characterization and assessment of therapeutic response. 18 More importantly, it may become the means for a paradigm shift to our mode of scientific reasoning, where interdisciplinary collaboration becomes fundamental toward a holistic view of the biological mechanisms.
In Sec. II we present how the attempt to combine the various fragments of information gave rise to data integration. Sections III and III A contain the current status and future steps in MI technology. In Sec. IV we present how MI can become the vehicle for a new paradigm shift in medical physics and our vision for the new scientific and working environment that the medical physicist is going to be part of in the years to come.
II. DATA INTEGRATION
The medical diagnostic and prognostic tasks have motivated researchers to integrate the available data, in an attempt to combine the various fragments of information. Biomedical data integration can be defined as the procedure for the creation of a single, uniform interface to query the data stored in many heterogeneous databases.
Integration means much more than obtaining the data in digital form or even reducing diverse data to a common form. Care must be taken so that integrated data serve the end-users' ͑clinicians'͒ requirements and reflect in a well specified manner the medical hypothesis that warranted the specific examination. In general, integration can be the ag-TABLE I. The advent of MI allows the design of structured experiments aiming to reveal/find the causal relationships among variables and mechanisms concerning various levels of biological organization. A unified biomedical theory may be built using top-down and bottom-up approaches ͑as well as combinations thereof͒ for diagnosis or prognosis. This theory could causally connect the mutations of specific genes ͑sequence analysis͒ with a characteristic pattern of gene coexpressions ͑analysis of microarrays͒, the abnormal value of some immunochemical parameters ͑flow cytometry, microscopy͒, the manifestation of certain macroscopic anatomical or functional anomalies ͑CT, SPECT, etc.͒ and finally with the observation of specific clinical signs and symptoms. All modalities are in vivo unless otherwise indicated. gregation of semantically similar data from multiple heterogeneous sources ͑vertical integration͒; the composition of semantically complementary data from multiple heterogeneous sources ͑horizontal integration͒; and the standardization of access to semantically similar information at disparate sources ͑integration for application portability͒. For example, with vertical integration morphology information can be obtained through the combination of data from both CT and ultrasound ͑US͒; horizontal integration would be beneficial when both anatomy and physiology of a specific region are sought for. Integration for application portability would make comparable data originating from imaging apparatuses of different specifications, e.g., 512ϫ 512 and 256ϫ 256 image matrices.
The attempts for data integration have comprised a strenuous track of research within the field of medical informatics and a number of issues still need to be addressed. Some of these issues are the partial availability of databases, the controversial privacy issues, the fact that useful information lies in the natural language text of the scientific papers, and, perhaps most importantly, the lack of appropriate standards. 19 It was soon evident that obtaining multiple representations of the same entity, e.g., through CT, SPECT, or MRI, would enhance the ability of making better medical decisions. But the efficient combination of available variables toward better medical diagnosis and prognosis had been a high-complexity process, even when the available data were of the high-level type, i.e., results of clinical and laboratory examinations.
With the advent of molecular data, the combination of multimodality information reached a higher level of complexity. It became obvious that analytical approaches are unable to compensate for such complexity. From the thousands of variables stored in the integrated databases only the variables relevant to specific clinical problems should be considered. This calls for the development of efficient ways for variable description and management. One such way is building additional data structures-called metadata-that describe the characteristics of stored variables. Metadata arranged in schemata can represent the hierarchical structures of these characteristics and help us build frameworks for the integration of contextual information from the clinician's point of view. Statistical modeling and procedures for statistical learning can also be helpful, providing methodologies for feature extraction and data reduction.
Evidence-based medicine ͑EBM͒ has been recently established as the approach of choice to medical practice. EBM uses the best current evidence and statistical methods to justify the value of therapeutic decisions in an individual patient. What it effectively does is to identify similarities or matches between the specific patient's patterns of clinical and laboratory data and scientifically valid evidence. The availability of integrated data will allow us to describe all the relevant variables and their interactions in a deep and structured manner and finally to expose the underlying mechanisms that give rise to these patterns. We could then obtain better specifications of one's health status and consequently aim at personalized treatment or prevention.
III. MOLECULAR IMAGING
Since understanding is our goal, seeking optimal methods for production and analysis of integrated data might prove a futile task. Drawing an example from the field of machine learning, one can find a number of methodologies that are capable of performing efficient multivariate discrimination of cases into classes but provide little or no insight on how these variables are semantically connected. Expanding our focus from a possibly blind analysis of integrated data to the quest for understanding the inter-relationship among the variables and governing biological mechanisms can allow us to obtain a holistic view of human organism.
MI is the field of research that provides an opportunity for convergence of two seemingly disparate interests: the clinical interest in providing better health care and the basic scientists' interest in explaining the biological mechanisms that give rise to the phenotypic manifestations. Based on this convergence, productive alliances between medical physicists and radiologists, on one hand, and molecular and cellular biochemists, on the other hand, are currently driving MI. 20 MI can be broadly defined as the in vivo characterization and measurement of biologic processes at the cellular and molecular level. 21 Receptors, transporters, extracellular enzymes, and intracellular macromolecules are all potential targets for MI. MI encompasses a broad set of technologies that couple imaging modalities and contrast agents with molecular specificity. MI can be divided into two general approaches for generation of image contrast. In the first approach, contrast reagents are engineered to interrogate endogenously expressed proteins or nucleic acids and in the second the reporter genes are transfected for expression regulated by environmental or tissue factors. 22 It is expected that chemically engineered exogenous reporters will be more useful than genetically encoded reporters. 20 The contrast agents, called molecular probes or tracers, consist of a signaling component that emits a detectable signal and a targeting component that confers localization. Modalities used in MI include nuclear imaging, i.e., SPECT and PET, anatomical imaging, i.e., CT and MR imaging, optical imaging and US. 18 MI is possible with the existing imaging modalities because some degree of tissue ͑cell͒ inhomogeneity can be registered within the inherent spatial resolution limits of the resultant images. 23 Despite the term, current MI modalities used to image animals and patients do not visualize individual molecules or even cells but rather populations thereof, since there are specific requirements for generating sufficient signal-to-noise ratios to render imaging possible. The challenge for remote imaging modalities ͑i.e., PET, SPECT, MRI, and optical imaging͒ is the direct imaging of DNA, 24 which is associated with problems of nonspecific and nontarget binding of imaging probes in case of polymorphisms. Direct targeting of mRNA is also challenging, as it requires one to one correlation of mRNA molecules with the imaging probes, whereas only 50 to thousands of mRNA molecules are present in every cell. These problems are solved in the case of protein imaging since proteins are present in quite higher amounts ͑thousands to millions of copies per cell͒, that make their imaging more feasible. 25, 26 By using carefully designed probes in order to target proteins that act as enzymes MI can provide an indirect measurement of characteristic signals that arise from the expression of specific DNA parts. While direct measurement seems infeasible, MI takes advantage of the enzymatic amplification of protein function.
Contrary to the paradigms followed until now, the underlying biological question rather than the technology itself should drive the choice of imaging technique. MI seeks to identify and evaluate specific molecular signals which in turn induce specific requirements for spatial resolution and sensitivity. PET and SPECT use contrast agents that are synthesized at sufficiently high specific activities and provide the required levels of image contrast. MRI, on the other hand, a preferred modality when high spatial resolution is required, suffers from the need for 4-6 orders of magnitude higher contrast agent concentration due to the indirect nature of enhancement produced by MRI contrast agents. 24 This introduces clinical risks of toxicity as well as the danger of contrast agent concentration, perturbing the underlying molecular signal that is being monitored by MRI. Similar trade-offs are intrinsic to US contrast agents, optical imaging techniques, and even x-ray contrast agents.
III.A. Future steps in MI technology
Merging PET with optical imaging techniques seems technically feasible and there are already published results toward this direction. 27 Such a system ͑OPET͒ is capable of detecting both high-energy gamma rays and optical wavelength photons and allows the noninvasively and repetitive imaging of small animal models in vivo for the presence of PET and optical signals. Thus, both technologies' tracers can be combined and provide simultaneous different information. The expected improvements in detector technology will make the construction of simultaneous OSPECT systems with similar advantages feasible.
More exotic technologies, coming from the world of high energy physics, are being investigated for potential medical applications. It is obvious that they have to be seen not as single imaging modalities but in combination with the already existing ones. For example, x-ray phase-contrast imaging reconstructs the projected absorption and refractive index distributions of an object and offers dramatically reduced noise levels with greatly enhanced imaging contrast. 28 Neutron imaging can offer alternative tools, since neutrons are highly penetrating. Therefore, it can image deeply seated body structures that cannot be reached by other probes. 29 Neutron stimulated emission computed tomography illuminates the body with fast neutrons ͑with energies between 1 and 10 MeV͒ and could identify malignancies by the way they change concentrations of chemical elements in tissue, long before cancer has begun to produce macroscopic anatomical changes. Terahertz ͑THz͒ spectroscopy can be used to image fatty tissue, bone, teeth, and thin slices of nonfatty tissue by using electromagnetic waves at THz frequencies. 30 Instruments
Nanoparticles have the potential to change the role of imaging technologies in diagnosis and therapy. They are colloidal vesicular systems that vary in size from 10 to 1000 nm with the drug and/or imaging probe of interest either entrapped therein or attached thereon. 31 Inherently, when echogenic nanoparticles are bound to surfaces, they can be modified for compatibility with MR, US, x ray, or nuclear imaging methodologies. 32 There are several examples that prove the advantages of such bimodal agents. For example, fluorine ͑ 19 F͒ MRI of cells labeled with different types of liquid perfluorocarbon nanoparticles produces unique and sensitive cell markers distinct from any tissue background signal. 33 Successful full body microSPECT/CT mouse imaging of Cd 125m Te/ ZnS NPs linked to either a monoclonal antibody against mouse lung thrombomodulin ͑mAb 201B͒, or a control antibody ͑mAb 33͒, has shown that nanoparticles conjugated to mAb 201B principally target the lungs while the nanoparticles coupled to mAb 33 accumulate in the liver and spleen. 34 Similarly, PET labeled nanoparticles have been successfully imaged. 35 PET and MRI studies are carried out in parallel due to the lack of combined imaging systems. 36, 37 It is estimated that simultaneous imaging of bimodal nanoparticles will maximize the benefits from the combination of nuclear medicine and MR information. 38 Other magnetic nanoparticles can be caused to oscillate under the influence of an incident ultrasonic wave with the advantage of greater sensitivity due to the absence of a large background signal. 39 By the use of targeted gold nanoparticles, the combination of US with contrast enhanced photoacoustic imaging seems possible. This is proposed as a visual tool to compound molecular and structural information for early stage prostate cancer detection. 40 An additional promise of endogenous expression, where contrast reagents are engineered to interrogate endogenously expressed proteins or nucleic acids, is the combination of imaging with therapeutic reagents such that they can both be optimized in an iterative fashion. The effect of therapeutic reagents can give rise to modified signals which in turn can be identified with the use of different contrast reagents. The latter can give evidence for new therapeutic pathways, etc. It is now recognized that many of the survival attributes of neoplastic cells are determined by proteins involved in mechanisms of antiapoptosis, cell cycle regulation, and damage repair. 41 Therapeutic radiation-following the definition of the underlying molecular features of cancer cells by MIcan act as focused biology ͑i.e., producing molecular events in the irradiated tissue͒ that targets molecular entities other than DNA, offering new opportunities for therapeutic attacks on cancer cells.
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IV. UNIFICATION
In its course through history research often passes through stages of conformity. In our opinion, we are currently experiencing such a stage. New research hypotheses are rare-on a global scale-and most research is conducted in deference to the mandates of what has been established as a valid research trend at that particular time. Researchers often publish results originating from repetitions of experiments already performed elsewhere, perhaps responding to an indirect mandate of the peer-review publication procedure. A possible validation of results is preferred to the statement and pursuit of new hypotheses. Technology offers an alibi for this attitude, shifting our focus to its impressive advances. However, we are now entering a new era in which technological progress alone does not suffice. 43, 44 The current challenge for medical physics is the development of a framework that will lead us from the deepening of our knowledge in the details of specific phenomena to the widening of our scope in understanding the underlying etiologies. From the deductive mode of reasoning, we must march to the statement of new hypotheses and consequently invent the experiments to test them.
A new paradigm must be followed in order to reverse this trend of conformity and provide new pathways for research. MI can facilitate such a paradigm. Lying between the gene and the cell level, it provides images and measurements of populations of molecules, thus incorporating the statistical nature of the mechanisms which give rise to the measured quantities. New variables, which emerge through the analysis of this new kind of data, could describe these quantities efficiently and offer a connection with modalities pertinent to other levels of complexity of the human organism. It is the potential for broadening the scope of our goals within biology and medicine that makes MI unique. Apart from aiming at improved diagnostic and prognostic performance, MI can become a vehicle for the development of conceptual frameworks that transect the entire range of information levels.
Clinicians have traditionally treated the various levels of available data in a top-down fashion: they start with clinical manifestations of diseases and they attempt to find relations with specific patterns in low-level molecular data. On the other hand, biologists take the opposite direction: they perform research on DNA sequences and gene expression, and they try to link them with specific diseases, following a bottom-up approach inside the multilevel data space. This observation does not necessarily exclude sideway movements inside the same level or even opposite direction steps within the main trend. For example, biologists, performing gene coexpression experiments with the use of microarray technology, might need to go along the top-down direction to investigate through sequencing whether a polymorphism causes the apparent behavior. Similarly, clinicians are moving bottom-up when their low-level findings are attributed to clinical cases similar to the ones they originated from.
The case of rheumatoid arthritis ͑RA͒ can be used as an example of a disorder in which various imaging modalities are used to provide details at different levels of information. The tissues within a joint, usually harmed in patients suffering from RA, can be examined with tomographic techniques 45, 46 that depict the phenotypic manifestation of the illness and/or inflammation. Physicists have helped in this endeavor by working in the area of CT and MRI for many years, initially in the concept of tomographic imaging and later on, in developing dual energy CT modalities and functional MRI. Research studies in functional imaging modalities such as in the areas of optimizing data acquisition ͑time of flight PET͒, 47 scatter modeling, 48 CT based attenuation correction, 49 etc., require a strong physics background.
Besides, US is used for both diagnostic evaluation of erosions or synovitis and therapeutic follow-up, 50 whereas metabolizing bone can be observed with the aid of functional imaging by using PET ͑Ref. 51͒ and SPECT. 52 At molecular level, techniques, such as bioluminescence and fluorescence reflectance imaging, allow imaging of the delivery of therapeutic agents. To this direction, physicists have worked in many areas like tomographic optical imaging 53 and combined procedures of PET and optical imaging. 27 Furthermore, microarrays allow an open-ended survey to comprehensively identify the fraction of genes that define each sample's unique expression. 54 IL-17RA and IL-17RC were found to be overexpressed in RA peripheral whole blood, 55 while oligonucleotide microarrays have already been used in order to elucidate the molecular effects of antirheumatic drugs on human chondrocyte gene expression. 56 Research studies conducted by physicists have contributed in optimizing the techniques for better signal acquisition and better microarray image segmentation. 57 RT-PCR has been used in order to evaluate the potent effects of vasoactive intestinal peptide in human RA, 58 while the efficacy of a soluble ligand of CD200R has been evaluated in established collagen-induced arthritis in mice. 59 Additionally, southern blot, 60 northern blot, 61 and western blot 62 analyses have been used in measuring the expression of different cell types in RA. Optical imaging techniques have also emerged in the field of RA ͑Ref. 63͒ with the more recent advancement of coupled photoacoustic tomography and image reconstruction in joint inflammatory diseases with high sensitivity and accuracy ͑Fig. 1͒. 64 A model that would efficiently combine these multilevel fragments of information is still missing. Such a model would not only result in the improvement of the diagnostic and therapeutic potential of modern medicine but would also render the-now hidden-underlying mechanisms of interactions observable and explainable, bridging the gap between the phenotypic and the genotypic level. The concept of probability as a measure of plausibility constitutes a core notion for the modeling of biological mechanisms. The Bayesian perspective to probability can assist researchers in this task with its main advantage being that it allows reasoning based on subjective evidence accumulated in a stepwise manner. Bayesian networks [65] [66] [67] [68] constitute a graphical representation of knowledge, 69 explicitly representing complexity, and simultaneously an efficient tool for inference and reasoning under uncertainty. They are being extensively used in medicine [70] [71] [72] and biology. [73] [74] [75] [76] [77] They are learning from data and their modularity allows the inclusion of fragments of knowledge into larger reasoning systems. Therefore, Bayesian networks can effectively capture the various constraints posed by the different disciplines involved in MI. It is our belief that Bayesian theory can provide a solid and transpar-ent chassis for the conduct of experiments that will justify the steps toward a unification of our theories for the mechanisms under study.
The apparent bottleneck in the exploitation of the currently available data cannot only be attributed to the relative hysteresis in the development of information management methodologies as compared to the technological breakthrough. What is more significant is the ignorance of the sources of variance and its magnitude in our measurements.
Physicists have a key role in identifying these sources of statistical noise through their comprehension of the physical processes governing the instrumentation used. Joining a team consisting of biologists, physicians, and bioinformaticists, medical physicists will have distinct and important roles in estimating the magnitude of this noise, designing improved measurement apparatus, providing the physical constraints bounding the proposed hypotheses, and setting-up novel experiments to test them. The introduction of nanoparticles ͑described previously͒ may be considered as an example of this procedure. Their use within MI gives rise to a number of considerations relevant to their characteristics. Paramagnetic, radioactive, and chemical properties of nanoparticles and imaging probes which are bound to them, influence both the way they interact at the molecular level and the characteristics of their imaging. Medical physicists are studying how these properties affect parameters like spatial resolution, sensitivity, acquisition time, and dose and provide optimization guidelines specific to the particular task.
The emergence of MI offers the opportunity for studying mechanisms acting on different biologic organization levels. Medical physicists will be asked to provide support to the pursuit of a future unification theory incorporating the entire array of mechanisms underlying the phenotypic manifestations. Toward this end, a reorientation of medical physics is needed. Currently, most medical physicists dedicate a large part of their education and work in becoming specialists in a particular diagnostic modality or therapeutic apparatus. In this way, medical physicists acquire not only deep knowledge of the physical principles underlying the specific modality but work to optimize its applications. This leads to the rapid development of the modality with impressive results. Unfortunately, this overspecialization is not sufficient to address the issues that will be raised in the immediate future. The new scientific and working environment, which the medical physicist is going to be part of in the years to come, calls for developing a broader view of the scientific questions raised and the methodologies at hand within both medical physics education and research activities.
The education of medical physicists should aim at developing scientists with enhanced capabilities for synthesis. The syllabi of future medical physics courses will require substantial augmentation with carefully selected and interconnected topics from molecular and computational biology. These types of courses will familiarize physicists with concepts and methodologies they can use in their collaboration with scientists from other disciplines. MI can acquire a dominant position in these courses not only as an exposition of a new technology but mainly as a new means for understanding the mechanisms governing the function of the human organism at various levels of organizational complexity. Apart from research in the traditional fields of medical physics, additional research activities will then naturally unfold toward theoretical aspects of a unified conceptual framework.
V. DISCUSSION/CONCLUSION
From a DNA strand anomaly to a clinical symptom or sign, there are many different levels at which technology offers means for inspection. But since they have emerged at different points in our perpetual attempt to comprehend the structure and function of the human organism, imaging technologies constitute instruments of fragmentary value. In the continuum of interactions among the various entities that modern medicine and biology have revealed, each imaging modality covers efficiently only a narrow region. As technology advances, each modality becomes increasingly better in terms of precision within this continuum, shedding light to new mechanisms and processes. We are thus given the opportunity to build new theories that link the mechanisms relevant to one level with mechanisms relevant to another.
The design of new complex experiments will be needed, involving variables pertinent to many levels of biological organization. Obviously, MI is an interdisciplinary approach where end-user needs and challenges have to be well defined and clearly understood; clinicians define the diagnostic or therapeutic needs; biologists can define the biological phenomena that can be targeted; and physicists will have to investigate the appropriate physical processes and suggest imaging concepts. These will lead to the advancement of both science and technology. New theories will be developed and new conceptual frameworks will be established to include them. We thus have the opportunity to build genuine interdisciplinary collaborations within which the ideas originating from different disciplines will fuse and create a new core of thinking.
This is expected to affect the field of medical physics in its theoretical foundations. It is unlikely that its current structure can accommodate the increasing interactions with biology and medicine; new ways of thinking will be needed to meet new scientific challenges. We now have the possibility of performing a step into revolutionary science, 78 exploring alternatives to long-held, obvious-seeming assumptions. From an epistemological viewpoint, there are many similarities with the situation in physics at the dawn of the 20th century. Experimental data that could not be explained with the physical theories available at that time were partially accommodated by the Bohr atomic model and later with refinements made by Sommerfeld. However, only when the concept of the wave function and the Schrödinger equation appeared did quantum theory manage to describe and explain the mechanisms giving rise to the phenomena. The growth of the quantum theory offered a unifying framework for concepts initially bound to either the microscopic or macroscopic level and gave birth to electronics as a new discipline. Medical physics might follow the same route. Its theoretical expansion may develop as a result of our attempt to provide a unifying view of the biological processes from the molecule to the entire organism. MI may become both a technology that produces experimental data not yet accounted for by current theories and a bridge through which fragments of knowledge will be assembled into a unified theory.
The role that medical physicists will play in this endeavor cannot be predicted precisely. It will be the result of a number of factors ranging from the reorientation of medical physics courses' syllabi to the self-motivation and degree of engagement of each individual medical physicist. Medical physicists should closely collaborate with biologists, biochemists, physicians, and bioinformaticists. They should take a strategic position due to their diverse role in both providing new results in the imaging research as well as giving feedback to the research of other disciplines. 
